CLINICAL TRIALS PROFILE FOR CATAFLAM
✉ Email this page to a colleague
All Clinical Trials for CATAFLAM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00276419 ↗ | Treatment of Breast Pain Using A Medication (Diclofenac) Applied to the Skin | Terminated | Mayo Clinic | Phase 2/Phase 3 | 2005-06-01 | The study was a randomized, double-blinded, crossover trial of topical diclofenac and placebo (10 weeks of each) for the treatment of noncyclic breast pain. |
| NCT00474136 ↗ | Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium | Completed | Javelin Pharmaceuticals | Phase 1 | 2007-03-01 | The purpose of this study is to assess the pharmacokinetic parameters of intravenous diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved reference product. |
| NCT00548678 ↗ | Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers | Completed | Javelin Pharmaceuticals | Phase 1 | 2007-10-01 | This study will assess platelet function and safety in healthy male volunteers following doses of intravenous diclofenac compared to oral diclofenac (Cataflam), intravenous ketorolac and oral aspirin. |
| NCT01762306 ↗ | Efficacy of Diclofenac on Pain During Endometrial Sampling | Unknown status | Mahidol University | N/A | 2012-11-01 | Abnormal uterine bleeding is common in Thai women. Traditionally, because of a larger number of patients, the diagnosis of its cause is performed via fractional curettage under local anesthesia such as paracervical nerve block or intravenous meperidine. Pain is one of a common adverse effect of this procedure and this topic should be concerned by a responsible doctor. NSAIDs, Diclofenac Potassium in this study, is known as a drug which is effective for pain control and is as effective as coxib in acute pain management. Because of its cost, easy accessible and easy administration, Diclofenac Potassium was selected to be used in this study. Its onset of action is about 1 hour and only one dose of this drug do not cause any serious side effects. The hypothesis of this study is that "Diclofenac Potassium has an additional effectiveness for acute pain control in patients undergoing fractional curettage under paracervical nerve block due to abnormal uterine bleeding" Double blind randomised controlled trial was performed in this study with 45 patients included in each group. |
| NCT01812538 ↗ | A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects | Completed | Hospira, Inc. | Phase 1 | 2009-05-01 | This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay sensitivity by evaluating the baseline-adjusted effect of a single oral (PO) moxifloxacin 400 mg dose on ventricular repolarization in healthy subjects compared to placebo. Other secondary objectives are as follows: - To evaluate the effect of DIC075V on ventricular repolarization in healthy subjects compared to placebo at the Tmax of diclofenac and hydroxypropyl-β-cyclodextrin (HPβCD). - To determine if there is a pharmacokinetic/pharmacodynamic (PK/PD) relationship between the duration of the QTc intervals and diclofenac and HPβCD plasma concentrations. - Obtain additional pharmacokinetic (PK) information on diclofenac and HPβCD in healthy subjects. - Provide additional safety information. |
| NCT01812538 ↗ | A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects | Completed | Hospira, now a wholly owned subsidiary of Pfizer | Phase 1 | 2009-05-01 | This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay sensitivity by evaluating the baseline-adjusted effect of a single oral (PO) moxifloxacin 400 mg dose on ventricular repolarization in healthy subjects compared to placebo. Other secondary objectives are as follows: - To evaluate the effect of DIC075V on ventricular repolarization in healthy subjects compared to placebo at the Tmax of diclofenac and hydroxypropyl-β-cyclodextrin (HPβCD). - To determine if there is a pharmacokinetic/pharmacodynamic (PK/PD) relationship between the duration of the QTc intervals and diclofenac and HPβCD plasma concentrations. - Obtain additional pharmacokinetic (PK) information on diclofenac and HPβCD in healthy subjects. - Provide additional safety information. |
| NCT02007161 ↗ | Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers | Unknown status | Katholieke Universiteit Leuven | N/A | 2013-12-01 | Investigate the supersaturation and precipitation behaviour of diclofenac in the stomach of healthy volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CATAFLAM
Condition Name
Clinical Trial Locations for CATAFLAM
Trials by Country
Clinical Trial Progress for CATAFLAM
Clinical Trial Phase
Clinical Trial Sponsors for CATAFLAM
Sponsor Name
